# ğŸ“… Daily Report - 2025-11-17

> ä»Šæ—¥ç­›é€‰å‡º **33** æ¡å†…å®¹ï¼Œæ¥è‡ª **4** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ“° å…¬ä¼—å·

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
çŒªè‚¾äººç§»æ¤åœ¨å…ç–«æ’æ–¥æœºåˆ¶ç ”ç©¶ä¸Šå–å¾—çªç ´ï¼›TP53çªå˜é‡å¡‘è‚ºè…ºç™Œè‚¿ç˜¤å¾®ç¯å¢ƒï¼Œå½±å“å…ç–«æ²»ç–—å“åº”ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- å¿ƒè„çº¤ç»´åŒ–é€†è½¬ä¸é‡ç¼–ç¨‹ï¼šGata4ç›´æ¥æŠ‘åˆ¶Meox1ï¼Œä¸ºHFpEFæä¾›æ–°ç­–ç•¥ã€‚
- è‚¿ç˜¤å¾®ç¯å¢ƒä¸å…ç–«æ²»ç–—ï¼šTP53çªå˜å½±å“è‚ºè…ºç™ŒTMEï¼›CAF-ç™Œç»†èƒé€šè®¯ä»‹å¯¼PARPiè€è¯ï¼›ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰çš„è¯†åˆ«ä¸äºšç¾¤åˆ†æã€‚
- å™¨å®˜ç§»æ¤å…ç–«ï¼šå¤šç»„å­¦æ­ç¤ºçŒªè‚¾äººç§»æ¤å…ç–«æ’æ–¥æœºåˆ¶ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- å¤šç»„å­¦è”åˆåˆ†æï¼šå•ç»†èƒã€ç©ºé—´è½¬å½•ç»„ã€å…ç–«å—ä½“åº“æµ‹åºã€æ·±åº¦è›‹ç™½è´¨ç»„å­¦ç­‰ï¼Œç”¨äºè§£æå¤æ‚ç”Ÿç‰©å­¦é—®é¢˜ã€‚
- æ–°å‹å¯è§†åŒ–å·¥å…·ï¼šbubbleHeatmapç”¨äºä»£è°¢ç»„å­¦æ•°æ®å¯è§†åŒ–ã€‚

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
å¤šç»„å­¦æ•´åˆæ­ç¤ºç™Œç—‡å¹¿è°±è€è¯æœºåˆ¶åŠæ²»ç–—é‡ç¼–ç¨‹ç­–ç•¥ï¼›TREM2+ å·¨å™¬ç»†èƒæµ¸æ¶¦æ˜¯ç´«æ‰é†‡è¯±å¯¼ä¹³è…ºç™Œè‚ºè½¬ç§»çš„å…³é”®ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- æ•´åˆå¤šç»„å­¦æ•°æ®ï¼ˆè½¬å½•ç»„ã€ä»£è°¢ç»„ç­‰ï¼‰è§£æç™Œç—‡å¹¿è°±è€è¯çš„åˆ†å­æœºåˆ¶ã€‚
- æ¢è®¨TREM2+ å·¨å™¬ç»†èƒåœ¨ç´«æ‰é†‡æ²»ç–—å¼•å‘ä¹³è…ºç™Œè‚ºè½¬ç§»ä¸­çš„ä½œç”¨ã€‚
- åˆ©ç”¨åŸºå› æ•²é™¤ç±»å™¨å®˜æ¨¡å‹ï¼ˆCdh1, Trp53, Smad4ï¼‰ç ”ç©¶å…¶åœ¨ç™Œç—‡å‘ç”Ÿå‘å±•ä¸­çš„åŠŸèƒ½ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- åˆ©ç”¨é«˜é€šé‡æµ‹åºè¿›è¡Œè½¬å½•ç»„åˆ†æã€‚
- æ„å»ºåŸºå› æ•²é™¤çš„ç±»å™¨å®˜æ¨¡å‹è¿›è¡ŒåŠŸèƒ½ç ”ç©¶ã€‚

### ğŸ”¬ æœŸåˆŠæ–‡ç« 

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
*   PTEN ä¸¢å¤±é©±åŠ¨è‚¿ç˜¤å‘ç”Ÿçš„æ–°å‹æœºåˆ¶è¢«æ­ç¤ºï¼Œæ¶‰åŠ PI3KÎ² ç£·é…¸åŒ–å’Œ EPHA2/SRC/p-PI3KÎ²Y962 å¤åˆç‰©ç»„è£…ã€‚
*   RAS/BRAF V600E çªå˜å¯¹é”™é…ä¿®å¤ç¼ºé™·/å¾®å«æ˜Ÿä¸ç¨³å®šæ€§ç»“ç›´è‚ ç™Œè‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒçš„å½±å“é¦–æ¬¡è¢«æ·±å…¥æ¢è®¨ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
*   ç ”ç©¶ RAS/BRAF V600E çªå˜åœ¨ dMMR/MSI ç»“ç›´è‚ ç™Œè‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒä¸­çš„ä½œç”¨ã€‚
*   æ¢ç´¢ PTEN ä¸¢å¤±é©±åŠ¨è‚¿ç˜¤å‘ç”Ÿï¼ˆåŒ…æ‹¬ PI3KÎ² ç£·é…¸åŒ–ã€EPHA2/SRC/p-PI3KÎ²Y962 å¤åˆç‰©å½¢æˆï¼‰çš„å…·ä½“åˆ†å­æœºåˆ¶ã€‚
*   è¯„ä¼°åŒå…ç–«æ£€æŸ¥ç‚¹é˜»æ–­ç–—æ³•åœ¨å¾®å«æ˜Ÿä¸ç¨³å®šæ€§é«˜è¡¨è¾¾ç™Œç—‡ä¸­çš„ç–—æ•ˆåŠé€‚ç”¨äººç¾¤ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
*   åˆ©ç”¨ä¸‹ä¸€ä»£æµ‹åºï¼ˆNGSï¼‰æŠ€æœ¯åˆ†æåŸºå› çªå˜ã€‚
*   åº”ç”¨ BioID ç›¸äº’ä½œç”¨ç»„æŠ€æœ¯é‰´å®šè›‹ç™½ç›¸äº’ä½œç”¨ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
é¦–æ¬¡å‘ç°é˜¿å°”èŒ¨æµ·é»˜ç—… tau è›‹ç™½å½¢æˆæ·€ç²‰æ ·çº¤ç»´å‰ï¼Œä¼šå…ˆå½¢æˆå¯é€†çš„è½¯å›¢èšç‰©ï¼ŒæˆåŠŸæº¶è§£è¿™äº›å›¢èšç‰©å¯é˜»æ­¢åç»­çš„çº¤ç»´å½¢æˆåŠç¥ç»æŸä¼¤ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- æ­ç¤ºé˜¿å°”èŒ¨æµ·é»˜ç—… tau è›‹ç™½ç—…å˜çš„æ–°æœºåˆ¶ã€‚
- å¼€å‘é¶å‘ tau è›‹ç™½æ—©æœŸå›¢èšä½“çš„æ²»ç–—ç­–ç•¥ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- æˆåŠŸæº¶è§£ tau è›‹ç™½æ—©æœŸè½¯å›¢èšç‰©ï¼Œé˜»æ­¢å…¶è¿›ä¸€æ­¥èšé›†ã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (24æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **Circulation|Gata4ç›´æ¥æŠ‘åˆ¶Meox1é€†è½¬å¿ƒè„çº¤ç»´åŒ–ï¼Œè¿™ç¯‡å•ç»†èƒ+ç©ºé—´è½¬å½•ç»„è”åˆåˆ†ææ€è·¯ï¼Œå€¼å¾—å­¦ä¹ **
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°åšå£«
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå¿ƒè„ã€å•ç»†èƒã€ç©ºé—´è½¬å½•ç»„ã€ç©ºé—´ç»„å­¦ã€è½¬å½•ç»„
- ğŸ“ **æè¿°**ï¼šé¶å‘å¿ƒè„çº¤ç»´åŒ–æ²»ç–—HFpEFçš„æ–°ç­–ç•¥â€”â€”å¿ƒè„é‡ç¼–ç¨‹ä¸Gata4çš„çªç ´æ€§è§’è‰²ç ”ç©¶èƒŒæ™¯å°„è¡€åˆ†æ•°ä¿ç•™å‹å¿ƒåŠ›è¡°ç«­ï¼ˆHF
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg2NDcxMzYwNg==&mid=2247490732&idx=1&sn=2ab0ccc4211a3496da748d242c1facf1)

**2.** â­ **Nature |ç©ºè½¬ã€å•ç»†èƒã€å…ç–«å—ä½“åº“æµ‹åºå’Œæ·±åº¦è›‹ç™½è´¨ç»„å­¦ï¼Œå¤šç»„å­¦ç ”ç©¶çŒªè‚¾äººç§»æ¤å…ç–«æ’æ–¥æœºåˆ¶**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡é’±åŒå­¦
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€æµ‹åºã€å•ç»†èƒã€è›‹ç™½è´¨ç»„
- ğŸ“ **æè¿°**ï¼šçªç ´æ€§çŒªè‚¾äººç§»æ¤ç ”ç©¶æ­ç¤ºå…ç–«æ’æ–¥æœºåˆ¶ä¸ºå™¨å®˜çŸ­ç¼ºéš¾é¢˜æä¾›æ–°è§£
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&mid=2247495568&idx=1&sn=7e9eb344773569aacb8fb49d58de821c)

**3.** â­ **Nature Cancer | TP53 çªå˜é‡å¡‘è‚ºè…ºç™Œè‚¿ç˜¤å¾®ç¯å¢ƒï¼šä»åˆ†å­ç‰¹å¾åˆ°å…ç–«æ²»ç–—å“åº”çš„å¤šç»„å­¦çªç ´**
- âœï¸ **ä½œè€…**ï¼šå•ç»†èƒå¤©åœ°
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€cancerã€å…ç–«
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&mid=2247533670&idx=1&sn=64f6f9d26c324a8eca52143956572fa5)

**4.** â­ **æ­¦æ±‰å¤§å­¦è¢ç‰å³°/å´å¤©æ ¹å›¢é˜ŸTEMç»¼è¿° | MASH-HCCä¸­çš„ä»£è°¢-å…ç–«å¾®ç¯å¢ƒä¸²æ‰°ï¼šICIçš„å›°å¢ƒå’Œå¸Œæœ›**
- âœï¸ **ä½œè€…**ï¼šCellPresså…¨ç§‘å­¦
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€ä»£è°¢
- ğŸ“ **æè¿°**ï¼šç»¼è¿°é‡ç‚¹æ¦‚æ‹¬ç°æœ‰ä¸´åºŠæˆ–ä¸´åºŠå‰ç ”ç©¶ä¸­æœ‰æ½œåŠ›çš„å…ç–«ç›¸å…³ä»£è°¢è¯ç‰©ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&mid=2247658324&idx=3&sn=76760b198b05b2c68391e30851fae71b)

**5.** **bubbleHeatmapï¼šç”Ÿæˆç”¨äºå¯è§†åŒ–ä»£è°¢ç»„å­¦æ•°æ®çš„æ°”æ³¡çƒ­å›¾**
- âœï¸ **ä½œè€…**ï¼šäº‘ç”Ÿä¿¡
- ğŸ·ï¸ **å…³é”®è¯**ï¼šä»£è°¢ã€ä»£è°¢ç»„
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&mid=2247498475&idx=1&sn=7da80685dcb63c12e6cf59d7d9b0b32d)

**6.** **æœ€æ–°8+ç”Ÿä¿¡ï¼Œå¤šç»„å­¦è¯†åˆ«ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰ç»“æ„å¹¶è¿›è¡Œé’ˆå¯¹æ€§åˆ†æã€‚é¢„æµ‹é¢„ååŠå…ç–«æ²»ç–—ç–—æ•ˆï¼Œå€¼å¾—å€Ÿé‰´ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503964&idx=3&sn=532199a1ebba55b0a3c394d615df87ef)

**7.** **10æœˆæœ€æ–°26+ç”Ÿä¿¡ï¼Œå¤šç»„å­¦ç©ºé—´å…ç–«è°±åˆ†æç¡®å®šäº†ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰çš„äºšç¾¤å¹¶è¿›è¡Œæ·±å…¥åˆ†æï¼Œå»ºè®®æ”¶è—ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503964&idx=2&sn=67aa48eb1c14af52ea870ee5fe001b20)

**8.** **æœ€æ–°8åˆ†ç”Ÿä¿¡ï¼Œç©ºè½¬å¤šç»„å­¦åˆ†ææ­ç¤ºCAF-ç™Œç»†èƒé€šè®¯ä»‹å¯¼ PARPi è€è¯çš„å…¨æ–°æœºåˆ¶ï¼Œå†…å®¹å¾ˆå°‘ï¼Œä¼˜åŠ¿åœ¨äºè‡ªæµ‹æ•°æ®ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè€è¯ã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šè¿™ç¯‡å‘è¡¨äºã€Šnpj Precision Oncologyã€‹çš„ç ”ç©¶ï¼Œèšç„¦é«˜ç­‰çº§æµ†æ¶²æ€§åµå·¢ç™Œï¼ˆHGSOCï¼‰å¯¹èšè…º
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503964&idx=1&sn=c60a04560bf5e11f3f9b3c99f3a68a84)

**9.** **Immunityé‡ç£…ï¼šæ›¹é›ªæ¶›å›¢é˜Ÿæ­ç¤ºè‚¿ç˜¤å…ç–«æ–°æœºåˆ¶**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡äºº
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€å…ç–«
- ğŸ“ **æè¿°**ï¼šå…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ï¼ˆå¦‚æŠ—PD1æŠ—ä½“ï¼‰å½»åº•æ”¹å˜äº†ç™Œç—‡æ²»ç–—æ ¼å±€ï¼Œä½†ä¸´åºŠä¸­çº¦70%-90%çš„å®ä½“ç˜¤æ‚£è€…å¯¹å…¶æ— å“åº”æˆ–äº§ç”Ÿ
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248521&idx=4&sn=5451636477f28b6f96dc76dfc1763943)

**10.** **è¯¦è§£ï¼šæ°¨åŸºé…¸ä»£è°¢è¿‡ç¨‹**
- âœï¸ **ä½œè€…**ï¼šå°æä»£è°¢
- ğŸ·ï¸ **å…³é”®è¯**ï¼šä»£è°¢
- ğŸ“ **æè¿°**ï¼šæ°¨åŸºé…¸ä»£è°¢æ˜¯ä¸€ä¸ªå¤æ‚è€Œç²¾ç»†çš„ç”ŸåŒ–è¿‡ç¨‹ï¼Œæ¶‰åŠåˆ°æ°¨åŸºé…¸çš„åˆæˆã€åˆ†è§£ã€è½¬åŒ–ä»¥åŠä¸å…¶ä»–ä»£è°¢é€”å¾„çš„ç›¸äº’è”ç³»ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzYyNDMwNjg3Nw==&mid=2247484049&idx=1&sn=95853ad4131700754fd2198052dfc233)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 14 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-å…¬ä¼—å·)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (3æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰

**1.** **GSE309935 å¤šç»„å­¦æ•´åˆæ­ç¤ºå¹¿è°±è€è¯æœºåˆ¶åŠæ²»ç–—æ€§é‡ç¼–ç¨‹ç™Œç»†èƒçš„æœºä¼š**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€resistance
- ğŸ“ **æè¿°**ï¼šContributor : Ian MersichSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBroad drug resistance in cancer arises through diverse transcriptional, metabolic, and genetic adaptations, yet the shared molecular programs that sustain cross-resistant phenotypes remain incompletely defined. This study integrates PRISM drug-response data with transcriptomic, metabolomic, and mutational profiles to characterize the molecular features associated with broad drug resistance and to identify compounds capable of reversing resistance-associated gene signatures. Resistant cell lines exhibited coordinated activation of extracellular matrix remodeling, stress-adaptation pathways, and survival signaling, with NFE2L2 emerging as a central regulatory hub linking upstream mutations to oxidative-stress transcriptional programs. Multi-omic integration further revealed metabolic reprogramming as a conserved hallmark of resistance, and analyses of clinical cohorts demonstrated that resistance-associated alterations were associated with reduced progression-free survival. Computational perturbagen screening nominated compounds predicted to counteract resistance-associated transcriptional signatures. Experimental validation confirmed that rosiglitazone suppressed NFE2L2-associated gene expression programs and restored chemotherapy sensitivity in resistant models, supporting a scalable framework for rational phenotypic reprogramming. This GEO submission provides raw RNA-seq data generated from compound-treated OE19 cells used to experimentally validate candidate re-sensitization strategies.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309935)

**2.** **GSE285485 TREM2+å·¨å™¬ç»†èƒæµ¸æ¶¦æ˜¯ç´«æ‰é†‡æ²»ç–—å¼•èµ·çš„ä¹³è…ºç™Œè‚ºè½¬ç§»çš„æ½œåœ¨æœºåˆ¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancer
- ğŸ“ **æè¿°**ï¼šContributors : Yuqi Xing ; Hongquan Zhang ; Jun ZhanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMetastasis is a major cause of breast-cancer-related death and frequently occurs following paclitaxel neoadjuvant chemotherapy failure. Tumor microenvironment contributes to metastasis, while the role of specific host cells in lung metastases induced by paclitaxel (PTX) treatment remains poorly understood. Here, we demonstrate that PTX neoadjuvant chemotherapy promotes triggering receptor expressed on myeloid cells-2 (TREM2)-positive macrophage infiltration in the breast cancer tissues of patients. Meanwhile, we also show that more TREM2-positive macrophage infiltrates in breast cancer tissues of patients with lung -metastasized. Genetic TREM2 deficiency decreases breast cancer lung metastases induced by PTX treatment in vivo, suggesting that TREM2-positive macrophages are essential for PTX-promoting lung metastasis of breast cancer. We further reveal that PTX promotes tumor cell secretion of fibroblast growth factor 2 (FGF2), triggering TREM2 transcription via upregulating its transcriptional factor early growth response-1 (EGR1) in macrophages. Increased TREM2 activates epithelial-mesenchymal transition (EMT)-related cytokine secretion in macrophages, inducing tumor cell lung metastases. Targeting TREM2 significantly suppressed lung metastasis in breast-cancer-bearing mice. Our findings establish that tumor-cell-derived FGF2 induced by paclitaxel treatment upregulates TREM2 in myeloid macrophages, which in turn promotes the EMT of neighboring tumor cells through cytokine secretion. Our results highlight TREM2 as a potential therapeutic target to mitigate lung metastasis due to PTX treatment.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285485)

**3.** **GSE218151 Cdh1 å’Œ Trp53 æ•²é™¤ç±»å™¨å®˜ï¼ŒCdh1ã€Trp53 å’Œ Smad4 æ•²é™¤ç±»å™¨å®˜ RNA æµ‹åº**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šsequencing
- ğŸ“ **æè¿°**ï¼šContributors : Jun W Park ; Hyeok W An ; Sang H SeokSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusTo investigate the function of Smad4, we established Cdh1 and Trp53 Knockout organoid, Cdh1, Trp53 and Smad4 Knockout organoid linesWe then performed gene expression profiling analysis using data obtained from RNA-seq of 4 different cells at two time points.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE218151)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (5æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨5æ¡ï¼‰

**1.** â­ **RAS/BRAF V600E çªå˜å¯¹é”™é…ä¿®å¤ç¼ºé™·/å¾®å«æ˜Ÿä¸ç¨³å®šæ€§ç»“ç›´è‚ ç™Œè‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒçš„å½±å“**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€å…ç–«ã€å…ç–«å¾®ç¯å¢ƒ
- ğŸ“ **æè¿°**ï¼šSecret hovertext: ç›®çš„ï¼šå»ºè®®å¯¹ç»“ç›´è‚ ç™Œ ï¼ˆCRCï¼‰ çš„ dMMR/MSI è¿›è¡Œå¸¸è§„æ£€æµ‹ï¼Œä»¥è¿›è¡Œæ—å¥‡ç»¼åˆå¾ç­›æŸ¥ã€é¢„åå’Œæ²»ç–—æŒ‡å¯¼ã€‚åœ¨è½¬ç§»æ€§ç¯å¢ƒä¸­ï¼ŒRASBRAF çªå˜æŒ‡å¯¼æ²»ç–—å†³ç­–ã€‚è¿™äº›çªå˜å¯¹ MSI/dMMR CRC ä¸­è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒ ï¼ˆTiMEï¼‰ çš„å½±å“å°šä¸æ¸…æ¥šã€‚å®éªŒè®¾è®¡ï¼šä½¿ç”¨ä¸‹ä¸€ä»£æµ‹åº ï¼ˆNGSï¼‰ï¼ˆ500 å€è¦†ç›–ç‡çš„ 595-648 ä¸ªåŸºå› çš„ Tempus xT DNA-seq å’Œ Tempus xR å…¨å¤–æ˜¾å­ç»„æ•è· RNA-seqï¼‰å¯¹ 448 å I-IV æœŸ MSI/dMMR CRC æ‚£è€…è¿›è¡Œå›é¡¾æ€§åˆ†æã€‚MSI çŠ¶æ€æ˜¯é€šè¿‡ä½¿ç”¨ NGS è¯„ä¼° 44 æˆ– 239 ä¸ªä½ç‚¹æ¥ç¡®å®šçš„ã€‚ä½¿ç”¨å…ç–«ç»„ç»‡åŒ–å­¦ ï¼ˆIHCï¼‰ ç¡®å®š dMMRã€‚åˆ†æè‚¿ç˜¤çªå˜è´Ÿè· ï¼ˆTMBï¼‰ã€è‚¿ç˜¤æ–°æŠ—åŸè´Ÿè· ï¼ˆNTBï¼‰ã€PD-L1ã€å…ç–«æµ¸æ¶¦å’Œå…¸å‹å…ç–«é€šè·¯ï¼ˆ76 ä¸ªåŸºå› é›†ç‰¹å¾ï¼‰ã€‚ç»“æœï¼šè¯Šæ–­æ—¶çš„ä¸­ä½å¹´é¾„ä¸º 67 å²ï¼ˆèŒƒå›´ 21-86ï¼‰ï¼Œ59% ä¸ºå¥³æ€§ï¼Œ70%
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1989595651795693568/t)

**2.** **åŒå…ç–«æ£€æŸ¥ç‚¹é˜»æ–­åœ¨å¾®å«æ˜Ÿä¸ç¨³å®šæ€§ä¸­â€”â€”é«˜ç™Œç—‡â€”â€”æœ‰æ•ˆï¼Œä½†å¯¹è°ä»¥åŠä½•æ—¶æœ‰æ•ˆï¼Ÿ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç™Œç—‡ã€å…ç–«
- ğŸ“ **æè¿°**ï¼šSecret hovertext:
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1989128396465090560/t)

**3.** **è‚ºéƒ¨è‚¿ç˜¤è´Ÿè·å¯¹è‰¯å¥½ç»„ç»‡å­¦è‚¾æ¯ç»†èƒç˜¤ç»“æœçš„å½±å“ï¼šå„¿ç«¥è‚¿ç˜¤å­¦ç»„ç ”ç©¶ AREN0533 çš„æŠ¥å‘Š**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤
- ğŸ“ **æè¿°**ï¼šSecret hovertext: ä¸´åºŠè‚¿ç˜¤å­¦æ‚å¿—ï¼Œå°åˆ·å‰ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1989097221025542144/t)

**4.** **PTEN ä¸¢å¤±ä¿ƒè¿› PI3KÎ² ç£·é…¸åŒ–å’Œ EPHA2/SRC/p-PI3KÎ²Y962 å¤åˆç‰©ç»„è£…ä»¥é©±åŠ¨è‚¿ç˜¤å‘ç”Ÿ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤
- ğŸ“ **æè¿°**ï¼šSecret hovertext: è‚¿ç˜¤æŠ‘åˆ¶å› å­ PTEN çš„ç¼ºå¤±ä¼šé©±åŠ¨ç™Œç—‡è¿›å±•å’Œæ²»ç–—è€è¯æ€§ï¼Œä½†å°šæ— é’ˆå¯¹ PTEN ç¼ºé™·è‚¿ç˜¤çš„é¶å‘ç–—æ³•ã€‚åœ¨è¿™é‡Œï¼Œæˆ‘ä»¬ç¡®å®šäº†ä¸€ç§å…³é”®çš„æˆè¯æœºåˆ¶ï¼Œå…¶ä¸­ PTEN ä¸¢å¤±è¯±å¯¼ PI3KÎ²ç£·é…¸åŒ–ä»¥ä¿ƒè¿›è‚¿ç˜¤å‘ç”Ÿã€‚ä½¿ç”¨ BioID ç›¸äº’ä½œç”¨ç»„ï¼Œæˆ‘ä»¬å‘ç°äº†ç”± p-PI3KÎ²Y962 é©±åŠ¨çš„ PTEN æ— æ•ˆç»†èƒä¸­ç£·é…¸åŒ–ä¾èµ–æ€§ PI3KÎ²-EPHA2 ç›¸äº’ä½œç”¨ã€‚PTEN ä½œä¸ºé…ªæ°¨é…¸ç£·é…¸é…¶èµ·ä½œç”¨ï¼Œé€šå¸¸ä½¿ p-PI3KÎ²Y962 å»ç£·é…¸åŒ–ã€‚åœ¨ PTEN ç¼ºé™·çš„æƒ…å†µä¸‹ï¼Œå¢å¼ºçš„ p-PI3KÎ²Y962 ä¸ EPHA2 å’Œ SRC å½¢æˆå¤åˆç‰©ï¼Œå…¶ä¸­ä¸¤ç§æ¿€é…¶éƒ½æœ‰åŠ©äº PI3KÎ²ç£·é…¸åŒ–ï¼Œæ¿€æ´»è‡´ç™Œ pERK / c-MYC å’Œ pAKT é€šè·¯ã€‚æˆ‘ä»¬å¼€å‘äº†ä¸€ç§é€‰æ‹©æ€§ p-PI3KÎ²Y962 æŠ—ä½“ï¼Œå¯åœ¨ä¸´åºŠå‰æ¨¡å‹å’Œä¸´åºŠè‚¿ç˜¤æ ‡æœ¬ä¸­æ£€æµ‹ PTEN ç¼ºé™·è‚¿ç˜¤ä¸­çš„ p-PI3KÎ²Y962ã€‚ç ´å p-PI3KÎ²Y962 æŠ‘åˆ¶äº†å¤šä¸ª PTEN-null
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1989755441775751168/t)

**5.** **ä¸€ã€äºŒã€å¤šï¼šæœ‰å¤šå°‘ç»†èƒå¼•å‘è‚¿ç˜¤ï¼Ÿ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤
- ğŸ“ **æè¿°**ï¼šSecret hovertext:
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1989771015855648768/t)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰

**1.** **ç§‘å­¦å®¶èåŒ–æ—©æœŸè›‹ç™½è´¨å›¢å—ï¼Œé˜»æ­¢é˜¿å°”èŒ¨æµ·é»˜ç—…é€ æˆçš„æŸå®³ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šAlzheimer
- ğŸ“ **æè¿°**ï¼šResearchers found that tau proteins donâ€™t jump straight into forming Alzheimerâ€™s-associated fibrilsâ€”first they assemble into soft, reversible clusters. When the clusters were dissolved, fibril growth was almost entirely suppressed. This reveals a promising new strategy: stop the precursors, stop the disease.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2025/11/251115095914.htm)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| å…ç–« | 11 |
| è‚¿ç˜¤ | 8 |
| cancer | 4 |
| å•ç»†èƒ | 4 |
| ç”Ÿä¿¡ | 4 |
| ä»£è°¢ | 3 |
| é€šè·¯ | 2 |
| ç™Œç—‡ | 2 |
| å…ç–«å¾®ç¯å¢ƒ | 2 |
| ä»£è°¢ç»„ | 1 |
| æµ‹åº | 1 |
| è›‹ç™½è´¨ç»„ | 1 |
| è€è¯ | 1 |
| å¿ƒè„ | 1 |
| ç©ºé—´è½¬å½•ç»„ | 1 |
| ç©ºé—´ç»„å­¦ | 1 |
| è½¬å½•ç»„ | 1 |
| resistance | 1 |
| Alzheimer | 1 |
| ç¥ç» | 1 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (14æ¡)</summary>

<div class="details-content" markdown="1">

- [å›½è‡ªç„¶çƒ­ç‚¹â€œé€šè·¯è°ƒæ§â€æ€ä¹ˆç”¨ï¼Ÿè¿™ç¯‡cAMP/PKA/CREBé€šè·¯+çªè§¦å¯å¡‘çš„éªŒè¯æ€è·¯å¤ªæ¸…æ™°](https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&mid=2247497914&idx=1&sn=94679f6ec7d1e7b410ae03abb6719806)
- [Cellï¼šæ›¹ç¿/è–›å¤©/é™ˆè´ºé˜é‡Š5-HT1Aå—ä½“ä¿¡å·é€šè·¯é€‰æ‹©æ€§æœºåˆ¶å¹¶è®¾è®¡å‡ºæ–°å‹å¿«é€ŸæŠ—æŠ‘éƒè¯ç‰©åˆ†å­ | Cell Pressè®ºæ–‡é€Ÿé€’](https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&mid=2247658201&idx=2&sn=6e21cc0b86245f2d6192adcd40fbcb38)
- [è‡´è°¢æŠ€èƒ½æ ‘æ–‡ç« ï¼šå¦‚ä½•ç”¨å•ç»†èƒæ•°æ®åšä¸€ä¸ªç»†èƒäºšç¾¤ç‰¹å¼‚æ€§çš„é¢„åç›¸å…³signatureï¼Ÿ](https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&mid=2247547001&idx=1&sn=9602007dce6166bd3aba1ca90cf7890e)
- [ç»¼è¿°å†™ä½œå¿…å¤‡ï¼ç”Ÿç‰©ç½‘ç«™+ç”Ÿä¿¡ç½‘ç«™](https://mp.weixin.qq.com/s?__biz=Mzg2MTExNTkwNA==&mid=2247573273&idx=2&sn=699050d1ec08e0d6c475a04eda691916)
- [å…ç–«å›¾ä¹¦29å†Œï¼Œé¦–æ¨ã€Šå…ç–«ç”Ÿç‰©å­¦ã€‹ï¼](https://mp.weixin.qq.com/s?__biz=Mzg2MTExNTkwNA==&mid=2247573273&idx=1&sn=e4c24898c1379ad3a57ef86af7bef2a1)
- [ç™»æƒå¨æœŸåˆŠï¼èšç„¦é£Ÿç®¡é³ç™Œç ”ç©¶ï¼šä¸­å›½åŒ»å­¦ç§‘å­¦é™¢è‚¿ç˜¤åŒ»é™¢å›¢é˜Ÿå‘ç°Notchä¿¡å·ä¿ƒè¡€ç®¡ç”Ÿæˆå…³é”®æœºåˆ¶](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248521&idx=7&sn=c0c7fa52dd321114eee63b36e97b21cb)
- [è™šæ‹Ÿæ„ŸæŸ“èƒ½è§¦å‘å…ç–«ååº”ï¼Ÿã€Šnature neuroscienceã€‹æ­ç¤ºå¤§è„‘çš„ç¥å¥‡é˜²å¾¡æœºåˆ¶](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248521&idx=6&sn=1bf6d89199bc3c9478aaefcea824426d)
- [åˆ©ç”¨ç”Ÿå­˜é¢„åæ¨¡å‹é¢„æµ‹ç™Œç—‡æ‚£è€…ç»“å±€ï¼šä»æ•°æ®åˆ†æåˆ°æ¨¡å‹è§£è¯»](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248521&idx=3&sn=0be64c234acab575580135c7d2bc1cf0)
- [ç™»é¡¶topçº§æœŸåˆŠï¼GWAS+å•ç»†èƒåˆ†æè§£å¯†ç–¾ç—…æœºåˆ¶ï¼Œè¿™æ³¢æ€è·¯å¿…é¡»å­¦ï¼](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248521&idx=2&sn=dfbbaa0d518fe59b12d4b0183c09ad53)
- [æ·±åœ³å¤§å­¦é‚¹ç«‹ä¸šå›¢é˜ŸTrends in Neurosciencesè§‚ç‚¹ä¸¨ä¹…åè¡Œä¸ºå¤§è„‘å¥åº·çš„ç¥ç»ç”Ÿç‰©å­¦åˆ†ç±»æ¡†æ¶](https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&mid=2247658324&idx=2&sn=3838e906cdec05d835fec7aa0c4cda63)
- [Cell å­åˆŠï¼šæ›²é™/åˆ˜å…‰æ…§/å¼ ç»´ç»®é˜æ˜æ ¸çº¤å±‚ç—…ä¸‰ç»´åŸºå› ç»„å¤±è°ƒæ ¸å¿ƒæœºåˆ¶](https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&mid=2247650102&idx=2&sn=e2c3771fe9879b02d3091b18d76d9f12)
- [æ–°å…ç–«åˆ†ç±»ç³»ç»Ÿï¼ç¦å»ºåŒ»ç§‘å¤§å­¦ç­‰å•ä½åˆä½œå‘æ–‡ï¼šæ›´ä¸ªæ€§åŒ–çš„èƒƒç™Œæ²»ç–—ç­–ç•¥](https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&mid=2656509912&idx=4&sn=bd81ca1c6b379669ddb0758bd900d7a5)
- [è‚¿ç˜¤ç»†èƒé‡ç¼–ç¨‹ï¼å¤æ—¦å¤§å­¦é™„å±è‚¿ç˜¤åŒ»é™¢ç­‰å•ä½åˆä½œå‘æ–‡ï¼šå¯å‡è½»è‚¿ç˜¤æ¶æ€§çš„èƒ°è…ºç™Œæ²»ç–—ç­–ç•¥](https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&mid=2656509912&idx=3&sn=6e354b36e11f6c42390b5d538f7c6558)
- [ã€ŠCancer Cellã€‹é‡ç£…ï¼šä¸ºä»€ä¹ˆé«˜è¾¾50%çš„è‚ ç™Œé¶å‘è¯ä¼šå¤±æ•ˆï¼Ÿå…ƒå‡¶ç«Ÿæ˜¯ç™Œç»†èƒâ€œå˜å½¢â€æˆäº†ç¬¬2ç§ç»†èƒï¼](https://mp.weixin.qq.com/s?__biz=MzkzMzY5NDk3NA==&mid=2247493212&idx=1&sn=25d171e77e50c24ca96b912bbf0a2b19)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-16 21:37*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*